Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055947 | 0.85 | NOS3 (0.53) | USP30NOS3NOS1NOS2AAK1 | |
| SCHEMBL13607944 | 0.83 | RIPK1 (0.44) | USP30HRH3RIPK1AAK1HTR6 | |
| SCHEMBL4050514 | 0.81 | PTGS2 (0.42) | NOS3NOS1NOS2KCNH2AAK1 | |
| SCHEMBL4063852 | 0.77 | USP30 (0.70) | USP30HRH3RIPK1KCNH2 | |
| SCHEMBL4055961 | 0.77 | GRIN1 (0.46) | NOS3NOS1NOS2 | |
| SCHEMBL4050811 | 0.76 | NOS3 (0.53) | USP30NOS3NOS1NOS2RIPK1 | |
| SCHEMBL4052795 | 0.76 | NOS3 (0.39) | USP30NOS3NOS1NOS2AAK1 | |
| SCHEMBL4055566 | 0.76 | SCD (0.41) | USP30NOS3NOS1NOS2AAK1 | |
| SCHEMBL4056184 | 0.75 | NOS3 (0.41) | NOS3NOS1NOS2AAK1 | |
| SCHEMBL4059137 | 0.75 | NOS3 (0.48) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | USP30 2997/4885HRH3 1429/4885NOS3 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.